The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 15 | 786.0x | 20.1x | Below average | |
Growth | 68 | 37.4% | 5.6% | Above average | |
Quality | 73 | 42.8% | 7.6% | Above average | |
Safety | 82 | -4.4x | 0.4x | Above average | |
Capital Return | 72 | — | 2.19% | Above average | |
Momentum | 39 | — | — | Near average | |
Sentiment | 42 | — | — | Near average |
BeOne Medicines Ltd. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy BeOne Medicines Ltd. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
Recent analyst reviews for ONC have shown remarkable stability with a slight positive bias, as the average price target rose by 0.31% over the past week to reach $399.11. Despite a slight decline of 0.5% over the last 30 days, the steady number of analysts at 15 and the confirmation from major institutions such as RBC Capital and Barclays of their positive ratings (Outperform/Overweight) reflect continued confidence in the company's operational trajectory.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.